Myrda, K.; Gąsior, M.; Dudek, D.; Nawrotek, B.; Niedziela, J.; Wojakowski, W.; Gierlotka, M.; Grygier, M.; Stępińska, J.; Witkowski, A.;
et al. One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock. J. Clin. Med. 2021, 10, 5059.
https://doi.org/10.3390/jcm10215059
AMA Style
Myrda K, Gąsior M, Dudek D, Nawrotek B, Niedziela J, Wojakowski W, Gierlotka M, Grygier M, Stępińska J, Witkowski A,
et al. One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock. Journal of Clinical Medicine. 2021; 10(21):5059.
https://doi.org/10.3390/jcm10215059
Chicago/Turabian Style
Myrda, Krzysztof, Mariusz Gąsior, Dariusz Dudek, Bartłomiej Nawrotek, Jacek Niedziela, Wojciech Wojakowski, Marek Gierlotka, Marek Grygier, Janina Stępińska, Adam Witkowski,
and et al. 2021. "One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock" Journal of Clinical Medicine 10, no. 21: 5059.
https://doi.org/10.3390/jcm10215059
APA Style
Myrda, K., Gąsior, M., Dudek, D., Nawrotek, B., Niedziela, J., Wojakowski, W., Gierlotka, M., Grygier, M., Stępińska, J., Witkowski, A., Lesiak, M., & Legutko, J.
(2021). One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock. Journal of Clinical Medicine, 10(21), 5059.
https://doi.org/10.3390/jcm10215059
